This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Q1 Earnings In Focus
by Zacks Equity Research
Q1 Earnings In Focus
Q1 Earnings Results, Theresa May Calls for New Snap Vote
by Mark Vickery
Earnings from BofA, Goldman, J&J an others follow a surprise address from British PM Theresa May calling for a new snap election.
J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.
J&J (JNJ) Beats on Q1 Earnings, Sales Miss Again
by Zacks Equity Research
JNJ beat on first quarter earnings - the company reported EPS of $1.83 while our consensus called for EPS of $1.77.
5 Hot Earnings Charts to Start the Week
by Tracey Ryniec
Earnings season is here and these companies have some of the best track records on Wall Street.
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates
by Zacks Equity Research
2017 is expected to be a strong year for drug stocks.
Why Juno Therapeutics' Stock Tumbled in the Past One Year
by Zacks Equity Research
Juno Therapeutics, Inc.'s (JUNO) stock has significantly underperformed Zacks classified Medical-Biomed/Genetics industry in the past one year.
Should You Sell Johnson & Johnson (JNJ) Before Earnings?
by Zacks Equity Research
Johnson & Johnson (JNJ) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Inovio's Ebola Vaccine Positive in Expanded Phase I Study
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.
Geron Stock Rises after Positive Interim Update on Imetelstat
by Zacks Equity Research
Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails
by Zacks Equity Research
Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
5 Drug Stocks for Your Portfolio this World Health Day
by Arpita Dutt
With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.
AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe
by Zacks Equity Research
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.
J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe
by Zacks Equity Research
Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).
Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
by Zacks Equity Research
We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.
AT&T & Verizon Suspend Marketing Advertisements from YouTube
by Zacks Equity Research
AT&T Inc. (T) and Verizon Communications Inc. (VZ) have decided to suspend their marketing campaign on Google's YouTube site.
5 Excellent ETFs for Your IRA
by Neena Mishra
Low-cost, diversified ETFs are excellent investment vehicles to build retirement wealth.
Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
by Arpita Dutt
Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
by Zacks Equity Research
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate
Large Cap ETF (IVV) Tops $100 billion in AUM
by Sweta Killa
IVV is the second ETF in the space that has managed to garner $100 billion in AUM after SPY.
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage
J&J Presents Positive Phase III Data on Psoriasis Candidate
by Zacks Equity Research
Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.